For twenty years, ophthalmologists worldwide used a cancer drug off-label to treat wet age-related macular degeneration, a use for which it was never formally approved. On July 24, 2026, the US Food and Drug Administration closed this gap: Lytenava (bevacizumab-vikg) is the first and only FDA-approved ophthalmic bevacizumab for this serious eye disease.
What Wet Age-Related Macular Degeneration Does to Vision
Wet AMD develops through abnormal blood vessel growth beneath the macula, the area of the retina responsible for sharp central vision. These new vessels are fragile, leaking fluid into surrounding tissue and destroying photoreceptors. Without treatment, wet AMD can cause severe vision loss within months.
Approximately 200 million people worldwide have some form of macular degeneration. The wet variant affects roughly 10 to 15 percent of them but accounts for most cases of severe vision loss. Around 20 million people globally live with wet AMD. The disease primarily affects adults over age 60.
Why Doctors Used an Off-Label Solution for Two Decades
Bevacizumab is originally a cancer drug. It blocks VEGF-A (vascular endothelial growth factor), which stimulates new blood vessel formation. This mechanism is also relevant for AMD, as the same compound that inhibits tumor blood vessels can slow pathological vessel growth in the eye.
Since the mid-2000s, ophthalmologists injected bevacizumab directly into the eye as a compounded medication. Pharmacies divided the large intravenous cancer drug vial into small individual doses for eye injections. This process lacked FDA-reviewed standards for sterility, potency, or labeling for many years.
Documented risks existed. Several US states experienced infection clusters, including a Streptococcus outbreak in Tennessee traced to contamination during compounding. The primary reason for sustained off-label use was price: USD 50 to 100 per injection, compared to USD 1,800 to 2,000 for approved alternatives ranibizumab (Lucentis, approved 2006) and aflibercept (Eylea, approved 2011).
How Lytenava Compares to Existing Therapies
Lytenava is not simply a regulated version of the compounded solution. The NORSE-TWO trial supporting FDA approval showed superior results versus ranibizumab as the comparison: 41 percent of Lytenava patients gained at least 15 letters on a standardized vision chart by month 11, compared to 23 percent with ranibizumab. Mean improvement in best-corrected visual acuity was 11.2 letters with Lytenava versus 5.8 letters with ranibizumab.
For context, ranibizumab was considered a breakthrough when approved in 2006 because it was the first to halt and sometimes reverse vision loss in AMD, replacing an era with no effective pharmacological options.
The 2011 CATT study (Comparison of AMD Treatments Trials) had shown that bevacizumab achieved comparable efficacy to ranibizumab in clinical tests. Lytenava advances beyond this equivalence: NORSE-TWO data demonstrate a statistically significant superior rate of complete vision improvement.
On price: In the United Kingdom, Lytenava has a list price of approximately GBP 470 per vial, totaling 3,290 to 4,230 pounds annually across 7 to 9 annual injections. This is substantially less than aflibercept or faricimab prices in the US at USD 1,800 to 2,000 per injection, but considerably more than the previous compounded option.
Three Conditions for Patient Access
Whether approval translates to patient benefit depends on three factors.
First, US pricing: Outlook Therapeutics has not yet announced the US price. Medicare Part B covers intravitreal injections. The critical question is whether payers will reimburse Lytenava or continue preferring the cheaper compounded option.
Second, managing the existing compounding practice: Approval and compounding do not always coexist smoothly in the US system. If Lytenava displaces the compounded alternative at substantially higher cost, this could create financial barriers for patients with limited insurance.
Third, availability and market launch: Outlook plans US commercial launch before end of 2026 and is developing reimbursement support and patient assistance programs.
For the estimated 20 million people worldwide with wet AMD, approval represents genuine progress. For the first time, there exists an ophthalmic bevacizumab formulation with verified quality standards, proven superiority in clinical endpoints, and potential to replace previously uncontrolled compounding practices.